Celldex (CLDX) Announces up to $175M Share Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
- Qualcomm shares fall on Intel warning and legal concerns
- Marvell Technology shares drop on Lumentum deal concerns
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Oracle shares drop on AI spending concerns and Microsoft criticism
- SpaceX stock drops on launch setback and sector selloff
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Celldex (CLDX) Prices Upsized 5.95M Share Offering at $42/sh
July 14, 2021 5:04 AM EDTCelldex Therapeutics, Inc. (Celldex or the Company) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 5,952,381 shares of its common stock at a public offering price of $42.00 per share. In connection with the offering, Celldex has granted the underwriters a 30-day option to purchase up to an additional 892,857 shares of common stock at the public offering price, less underwriting discounts and commissions.
Jefferies, SVB Leerink, Guggenheim Securities and Cantor are acting as the joint book-running managers for the offering. LifeSci Capital LLC and H.C. Wainwright & Co. are acting as co-lead... More
Celldex Therapeutics (CLDX) PT Raised to $61 at Cantor Fitzgerald
July 12, 2021 1:22 PM EDTCantor Fitzgerald analyst Kristen Kluska raised the price target on Celldex Therapeutics (NASDAQ: CLDX) to $61.00 (from $35.00) while maintaining a Overweight rating.
... MoreCelldex Therapeutics (CLDX) Gains on CDX-0159 Update, Which Has Drug 'In the Driver's Seat'
July 12, 2021 10:18 AM EDTCelldex Therapeutics (NASDAQ: CLDX) shares are ramping 30% in early trading Monday following updated data from the companys ongoing Phase 1b trial of CDX-0159 in patients with antihistamine refractory cold urticaria and symptomatic dermographism, the two most common forms of chronic inducible urticaria.
The update highlights several key metrics:
All 19/19 (100%) patients experienced a clinical response as assessed by provocation threshold testing; 18/19 (95%) experienced a complete response and 1/19 (5%) experienced a partial response.Rapid onset of responses after... MorePre-Open Stock Movers 07/12: (STFC) (CLDX) (SPI) Higher; (TBLT) (DIDI) (RKT) Lower (more...)
July 12, 2021 9:28 AM EDTPre-Open Stock Movers
State Auto Financial Corporation (NASDAQ: STFC) 189% HIGHER; Liberty Mutual Holding Company Inc., State Automobile Mutual Insurance Company, and State Auto Financial Corporation (NASDAQ: STFC) announced today that they have signed a definitive agreement pursuant to which Liberty Mutual would acquire State Auto Group, a super-regional insurance holding company headquartered in Columbus, Ohio. Under the terms of the agreement, State Auto mutual members will become mutual members of Liberty Mutual and Liberty Mutual will acquire all of the publicly held... More
Celldex Therapeutics (CLDX) PT Raised to $50 at H.C. Wainwright
July 12, 2021 6:21 AM EDTH.C. Wainwright analyst Joseph Pantginis raised the price target on Celldex Therapeutics (NASDAQ: CLDX) to $50.00 (from $36.00) while maintaining a Buy rating following updated Phase 1b data from the ongoing Phase 1b study of CDX-0159.
The analyst commented, "Celldex reported updated Phase 1b data from the ongoing Phase 1b study of... More



